USD
+$0.00
(+0.00%
)At Close (As of Sep 26, 2025)
$5.15B
Market Cap
-
P/E Ratio
-5.58
EPS
$70.65
52 Week High
$33.19
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $36M |
Total Revenue | $36M |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$272M |
Selling General And Administrative | $83M |
Research And Development | $225M |
Operating Expenses | $308M |
Investment Income Net | - |
Net Interest Income | $31M |
Interest Income | - |
Interest Expense | $31M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.5M |
Income Before Tax | -$207M |
Income Tax Expense | $8.2M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$215M |
Comprehensive Income Net Of Tax | - |
Ebit | -$272M |
Ebitda | -$270M |
Net Income | -$215M |
Field | Value (USD) |
---|---|
Gross Profit | $36M |
Total Revenue | $36M |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$272M |
Selling General And Administrative | $83M |
Research And Development | $225M |
Operating Expenses | $308M |
Investment Income Net | - |
Net Interest Income | $31M |
Interest Income | - |
Interest Expense | $31M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.5M |
Income Before Tax | -$207M |
Income Tax Expense | $8.2M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$215M |
Comprehensive Income Net Of Tax | - |
Ebit | -$272M |
Ebitda | -$270M |
Net Income | -$215M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Merus NV is a clinical-stage biotechnology company based in Utrecht, Netherlands, specializing in the discovery and development of innovative bispecific antibody therapies targeting cancer. With a strong focus on advancing its proprietary platforms, Merus leverages its unique technology to create targeted treatments that enhance immune responses against tumors. As it progresses through various stages of clinical development, Merus aims to address significant unmet medical needs in immuno-oncology, positioning itself as a key player in the evolving landscape of cancer therapeutics.